Replies to post #104206 on Biotech Values

[jq1234]

Im not trying to say Qnexa was perfect.

Sound like you are backpedaling. You said

At least all of VVUS risks were very hypothetical with no evidence.

There was plenty of evidence, not only from Qnexa trial, but also from long history of data from Topiramate.

By cardiac safety, I should have specified vulvopathy.

Cardiac safety is far beyond vulvopathy.

But based on the data and analysis available, I would take Qnexa over Lorquess any day of the week.

Thst's irrelevant. There is no gurantee you would make right decision.